Top

Published in:

01-12-2022 | Prostate Cancer | Non-Thematic Review

The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin

Authors: Shijie Sheng, Margarida Bernardo, Sijana H. Dzinic, Kang Chen, Wael A. Sakr

Published in: Cancer and Metastasis Reviews | Issue 4/2022

Abstract

Epithelial-specific Maspin is widely known as a tumor suppressor. However, while the level of maspin expression is inversely correlated with tumor grade and stage, emerging clinical evidence shows a correlation between seemingly better differentiated tumor cells that express Maspin in both the nucleus and the cytoplasm, (n + c)Maspin, with a poor prognosis of many types of cancer. Biological studies demonstrate that Maspin plays an essential role in stem cell differentiation. In light of the recently established characterization of primed stem cells (P-SCs) in development, we propose, for the first time, that cancer stem cells (CSCs) also need to undergo priming (P-CSCs) before their transition to various progeny phenotypes. We envisage major differences in the steady state kinetics between P-SCs and P-CSCs. We further propose that P-CSCs of carcinoma are both marked and regulated by (n + c)Maspin. The concept of P-CSCs helps explain the apparent dichotomous relationships of (n + c)Maspin expression with cancer diagnosis and prognosis, and is supported by the evidence from mechanistic studies. We believe that the potential utility of (n + c)Maspin as a molecular marker of P-CSCs may significantly accelerate the advancement in our understanding of the genesis of tumor phenotypic plasticity in response to changes of tumor microenvironments (TME) or drug treatments. The vulnerabilities of the cellular state of (n + c)Maspin-expressing P-CSCs are also discussed as the rationale for future development of P-CSC-targeted chemotherapeutic and immunotherapeutic strategies.

Zou, Z., Anisowicz, A., Hendrix, M. J., Thor, A., Neveu, M., Sheng, S., Rafidi, K., Seftor, E., & Sager, R. (1994). Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science, 263(5146), 526–529. https://doi.org/10.1126/science.8290962CrossRef

Sager, R. (1997). Expression genetics in cancer: shifting the focus from DNA to RNA. Proceedings of the National Academy of Sciences of the USA, 94(3), 952–955. https://doi.org/10.1073/pnas.94.3.952

Zhang, M., Hendrix, M. J. C., Pemberton, P. A., Sakr, W. A., & Sheng, S. (2017). An essential role of maspin in embryogenesis and tumor suppression-response. Cancer Research, 77(18), 5208–5210. https://doi.org/10.1158/0008-5472.CAN-17-1254CrossRef

Pierson, C. R., McGowen, R., Grignon, D., Sakr, W., Dey, J., & Sheng, S. (2002). Maspin is up-regulated in premalignant prostate epithelia. The Prostate, 53(4), 255–262. https://doi.org/10.1002/pros.10107CrossRef

Joensuu, K. M., Leidenius, M. H., Andersson, L. C., & Heikkila, P. S. (2009). High expression of maspin is associated with early tumor relapse in breast cancer. Human Pathology, 40(8), 1143–1151. https://doi.org/10.1016/j.humpath.2009.02.006CrossRef

A.K. Sood, A. K., Fletcher, M. S., Gruman, L. M., Coffin, J. E., Jabbari, S., Khalkhali-Ellis, Z., Arbour, N., Seftor, E. A., & Hendrix, M. J. (2002). The paradoxical expression of maspin in ovarian carcinoma. Clinical Cancer Research, 8(4), 2924–2932.

Frey, A., Soubani, A. O., Adam, A. K., Sheng, S., Pass, H. I., & Lonard, F. (2009). Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival. Histopathology, 54(5), 590–597. https://doi.org/10.1111/j.1365-2559.2009.03260.xCrossRef

Carozzi, F., Tamburrino, L., Bisanzi, S., Marchiani, S., Paglierani, M., Di Lollo, S., Crocetti, E., Buzzoni, C., Burroni, E., Greco, L., Baldi, E., & Sani, C. (2016). Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness? Journal of Cancer Research and Clinical Oncology, 142(1), 201–212. https://doi.org/10.1007/s00432-015-2015-1CrossRef

Chim, S. S., Tong, Y. K., Chiu, R. W., Lau, T. K., Leung, T. N., Chan, L. Y., Oudejans, C. B., Ding, C., & Lo, Y. M. (2005). Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proceedings of the National Academy of Sciences of the USA, 102(41), 14753–14758. https://doi.org/10.1073/pnas.0503335102CrossRef

10.

Huang, Y., Cai, L. W., & Yang, R. (2012). Expression of maspin in the early pregnant mouse endometrium and its role during embryonic implantation. Comparative Medicine, 62(3), 179–184.

11.

Gao, F., Shi, H. Y., Daughty, C., Cella, N., & Zhang, M. (2004). Maspin plays an essential role in early embryonic development. Development, 131(7), 1479–1489. https://doi.org/10.1242/dev.01048.

12.

Dzinic, S. H., Bernardo, M. M., Li, X., Fernandez-Valdivia, R., Ho, Y. S., Mi, Q. S., Bandyopadhyay, S., Lonardo, F., Vranic, S., Oliveira, D. S., Bonfil, R. D., Dyson, G., Chen, K., Omerovic, A., Sheng, X., Han, X., Wu, D., Bi, X., Cabaravdic, D., … Sheng, S. (2017). An essential role of maspin in embryogenesis and tumor suppression. Cancer Research, 77(4), 886–896. https://doi.org/10.1158/0008-5472.CAN-16-2219CrossRef

13.

Zhang, M., Magit, D., Botteri, F., Shi, H. Y., He, K., Li, M., Furth, P., & Sager, R. (1999). Maspin plays an important role in mammary gland development. Developmental Biology, 215(2), 278–287. https://doi.org/10.1006/dbio.1999.9442CrossRef

14.

Centonze, A., Lin, S., Tika, E., Sifrim, A., Fioramonti, M., Malfait, M., Song, Y., Wuidart, A., Van Herck, J., Dannau, A., Bouvencourt, G., Dubois, C., Dedoncker, N., Sahay, A., de Maertelaer, V., Siebel, C. W., Van Keymeulen, A., Voet, T., & Blanpain, C. (2020). Heterotypic cell-cell communication regulates glandular stem cell multipotency. Nature, 584(7822), 608–613. https://doi.org/10.1038/s41586-020-2632-yCrossRef

15.

Dzinic, S. H., Mahdi, Z., Bernardo, M. M., Vranic, S., Beydoun, H., Nahra, N., Alijagic, A., Harajli, D., Pang, A., Saliganan, D. M., Rahman, A. M., Skenderi, F., Hasanbegovic, B., Dyson, G., Beydoun, R., & Sheng, S. (2019). Maspin differential expression patterns as a potential marker for targeted screening of esophageal adenocarcinoma/gastroesophageal junction adenocarcinoma. PLoS ONE, 14(4), e0215089. https://doi.org/10.1371/journal.pone.0215089CrossRef

16.

Umekita, Y., Ohi, Y., Souda, M., Rai, Y., Sagara, Y., Sagara, Y., Tamada, S., A., & Tanimoto, A. (2011). Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer, Diagnostic Pathology, 6, 36. https://doi.org/10.1186/1746-1596-6-36.

17.

Barsky, S. H., Doberneck, S. A., Sternlicht, M. D., Grossman, D. A., & Love, S. M. (1997). “Revertant” DCIS in human axillary breast carcinoma metastases. The Journal of Pathology, 183(2), 188–194. https://doi.org/10.1002/(SICI)1096-9896(199710)183:2%3c188::AID-PATH898%3e3.0.CO;2-7CrossRef

18.

Zou, Z., Zhang, W., Young, D., Gleave, M. G., Rennie, P., Connell, T., Connelly, R., Moul, J., Srivastava, S., & Sesterhenn, I. (2002). Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. Clinical Cancer Research, 8(5), 1172–1177.

19.

Luo, M., Clouthier, S. G., Deol, Y., Liu, S., Nagrath, S., Azizi, E., & Wicha, M. S. (2015). Breast cancer stem cells: Current advances and clinical implications. Methods in Molecular Biology, 1293, 1–49. https://doi.org/10.1007/978-1-4939-2519-3_1CrossRef

20.

De Los Angeles, A., Loh, Y. H., Tesar, P. J., & Daley, G. Q. (2012). Accessing naive human pluripotency. Current Opinion in Genetics & Development, 22(3), 272–282. https://doi.org/10.1016/j.gde.2012.03.001CrossRef

21.

Messmer, T., von Meyenn, F., Savino, A., Santos, F., Mohammed, H., Lun, A. T. L., Marioni, J. C., & Reik, W. (2019). Transcriptional heterogeneity in naive and primed human pluripotent stem cells at single-cell resolution. Cell Reports, 26(4), 815–824 e814. https://doi.org/10.1016/j.celrep.2018.12.099.

22.

Gan, Q., Yoshida, T., McDonald, O. G., & Owens, G. K. (2007). Concise review: Epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. Stem Cells, 25(2007), 2–9. https://doi.org/10.1634/stemcells.2006-0383CrossRef

23.

Grignon, D. J., Ro, J. Y., Ordonez, N. G., Ayala, A. G., & Cleary, K. R. (1988). Basal cell hyperplasia, adenoid basal cell tumor, and adenoid cystic carcinoma of the prostate gland: An immunohistochemical study. Human Pathology, 19(12), 1425–1433. https://doi.org/10.1016/s0046-8177(88)80235-1CrossRef

24.

Yang, Y., Cheung, H. H., Tu, J., Miu, K. K., & Chan, W. Y. (2016). New insights into the unfolded protein response in stem cells. Oncotarget, 7(33), 54010–54027. https://doi.org/10.18632/oncotarget.9833.

25.

Trusler, O., Huang, Z., Goodwin, J., & Laslett, A. L. (2018). Cell surface markers for the identification and study of human naive pluripotent stem cells. Stem Cell Research, 26, 36–43. https://doi.org/10.1016/j.scr.2017.11.017CrossRef

26.

Cao, D., Wilentz, R. E., Abbruzzese, J. L., Ho, L., & Maitra, A. (2005). Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation. International Journal of Gastrointestinal Cancer, 36(1), 39–46. https://doi.org/10.1385/IJGC:36:1:039CrossRef

27.

Yang, Q., Roehrl, M. H., & Wang, J. Y. (2018). Proteomic profiling of antibody-inducing immunogens in tumor tissue identifies PSMA1, LAP3, ANXA3, and maspin as colon cancer markers. Oncotarget, 9 (3), 3996–4019. https://doi.org/10.18632/oncotarget.23583.

28.

Ma, P., & Schultz, R. M. (2008). Histone deacetylase 1 (HDAC1) regulates histone acetylation, development, and gene expression in preimplantation mouse embryos. Developmental Biology, 319(1), 110–120. https://doi.org/10.1016/j.ydbio.2008.04.011CrossRef

29.

Murakami, K., Gunesdogan, U., Zylicz, J. J., Tang, W. W. C., Sengupta, R., Kobayashi, T., Kim, S., Butler, R., Dietmann, S., & Surani, M. A. (2016). NANOG alone induces germ cells in primed epiblast in vitro by activation of enhancers. Nature, 529(7586), 403–407. https://doi.org/10.1038/nature16480CrossRef

30.

Dovey, O. M., Foster, C. T., & Cowley, S. M. (2010). Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proceedings of the National Academy of Sciences of the USA, 107(18), 8242–8247. https://doi.org/10.1073/pnas.1000478107CrossRef

31.

Wang, Y., Wang, L., Su, Z., Sun, W., Zhang, M., Yang, C., Zhou, J., Jiang, L., & Kong, X. (2021). POU2AF1 promotes MSCs adipogenesis by inhibiting HDAC1 expression. Adipocyte, 10(1), 251–263. https://doi.org/10.1080/21623945.2021.1918863CrossRef

32.

Kahali, S., Sarcar, B., Prabhu, A., Seto, E., & Chinnaiyan, P. (2012). Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response. FASEB Journal, 26(6), 2437–2445. https://doi.org/10.1096/fj.11-193706CrossRef

33.

Backe, S. J., Sager, R. A., Woodford, M. R., Makedon, A. M., & Mollapour, M. (2020). Post-translational modifications of Hsp90 and translating the chaperone code. Journal of Biological Chemistry, 295(32), 11099–11117. https://doi.org/10.1074/jbc.REV120.011833CrossRef

34.

Kahali, S., Sarcar, B., Fang, B., Williams, E. S., Koomen, J. M., Tofilon, P. J., & Chinnaiyan, P. (2010). Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia, 12(1), 80–86. https://doi.org/10.1593/neo.91422CrossRef

35.

Giaginis, C., Alexandrou, P., Delladetsima, I., Giannopoulou, I., Patsouris, E., & Theocharis, S. (2014). Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. Tumour Biology, 35(1), 61–71. https://doi.org/10.1007/s13277-013-1007-5CrossRef

36.

Su, J. M., Hsu, Y. Y., Lin, P., & Chang, H. (2016). Nuclear accumulation of heat-shock protein 90 is associated with poor survival and metastasis in patients with non-small cell lung cancer. Anticancer Research, 36(5), 2197–2203.

37.

Li, M., Zhuang, M., Zhang, L., Zheng, X., Yang, P., & Li, Z. (2016). Acetylation modification regulates GRP78 secretion in colon cancer cells. Sci Rep, 6, 30406. https://doi.org/10.1038/srep30406.

38.

Benarafa, C., & Remold-O’Donnell, E. (2005). The ovalbumin serpins revisited: Perspective from the chicken genome of clade B serpin evolution in vertebrates. Proceedings of the National Academy of Sciences of the USA, 102(32), 11367–11372. https://doi.org/10.1073/pnas.0502934102CrossRef

39.

Law, R. H., Irving, J. A., Buckle, A. M., Ruzyla, K., Buzza, M., Bashtannyk-Puhalovich, T. A., Beddoe, T. C., Nguyen, K., Worrall, D. M., Bottomley, S. P., Bird, P. I., Rossjohn, J., & Whisstock, J. C. (2005). The high resolution crystal structure of the human tumor suppressor maspin reveals a novel conformational switch in the G-helix. Journal of Biological Chemistry, 280(23), 22356–22364. https://doi.org/10.1074/jbc.M412043200CrossRef

40.

Sheng, S., Truong, B., Fredrickson, D., Wu, R., Pardee, A. B., & R. Sager, R. (1998).Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proceedings of the National Academy of Sciences of the USA, 95(2), 499-504.https://doi.org/10.1073/pnas.95.2.499.

41.

Biliran, H. Jr., & Sheng, S. (2001). Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Research, 61(24) 8676–8682.

42.

McGowen, R., Biliran, H. Jr., Sager, R., & Sheng, S. (2000). The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Research, 60(17), 4771–4778.

43.

Yin, S., Lockett, J., Meng, Y., Biliran, H. Jr., Blouse, G. E., Li, X., Reddy, N., Zhao, Z., Lin, X., Anagli, J., Cher, M. L., & Sheng, S. (2006). Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Research, 66(8) 4173–4181. https://doi.org/10.1158/0008-5472.CAN-05-3514.

44.

Li, X., Yin, S., Meng, Y., Sakr, W., & Sheng, S. (2006). Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin. Cancer Research, 66(18), 9323–9329. https://doi.org/10.1158/0008-5472.CAN-06-1578CrossRef

45.

Dzinic, S. H., Kaplun, A., Li, X., Bernardo, M., Meng, Y., Dean, I., Krass, D., Stemmer, P., Shin, N., Lonardo, F., & Sheng, S. (2013). Identification of an intrinsic determinant critical for maspin subcellular localization and function. PLoS ONE, 8(11), e74502. https://doi.org/10.1371/journal.pone.0074502CrossRef

46.

Bernardo, M. M., Meng, Y., Lockett, J., Dyson, G., Dombkowski, A., Kaplun, A., Li, X., Yin, S., Dzinic, S., Olive, M., Dean, I., Krass, D., Moin, K., Bonfil, R. D., Cher, M., Sakr, W., & Sheng, S. (2011). Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes & Cancer, 2(11), 1009–1022. https://doi.org/10.1177/1947601912440170CrossRef

47.

Kaplun, A., Dzinic, S., Bernardo, M., & Sheng, S. (2012). Tumor suppressor maspin as a rheostat in HDAC regulation to achieve the fine-tuning of epithelial homeostasis. Critical Reviews in Eukaryotic Gene Expression, 22(3), 249–258. https://doi.org/10.1615/critreveukargeneexpr.v22.i3.80CrossRef

48.

Yin, S. P., Li, X. H., Meng, Y. H., Finley, R. L., Sakr, W., Yang, H., Reddy, N., & Sheng, S. J. (2005). Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. Journal of Biological Chemistry, 280(41), 34985–34996. https://doi.org/10.1074/jbc.M503522200CrossRef

49.

Li, X., Kaplun, A., Lonardo, F., Heath, E., Sarkar, F. H., Irish, J., Sakr, W., & Sheng, S. (2011). HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells. Molecular Cancer Research, 9(6), 733–745. https://doi.org/10.1158/1541-7786.MCR-10-0505CrossRef

50.

Goldstein, A. S., Lawson, D. A., Cheng, D., Sun, W., Garraway, I. P., & Witte, O. N. (2008). Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proceedings of the National Academy of Sciences of the USA, 105(52), 20882–20887. https://doi.org/10.1073/pnas.0811411106CrossRef

51.

Bernardo, M. M., Kaplun, A., Dzinic, S. H., Li, X., Irish, J., Mujagic, A., Jakupovic, B., Back, J. B., Van Buren, E., Han, X., Dean, I., Chen, Y. Q., Heath, E., Sakr, W., & Sheng, S. (2015). Maspin expression in prostatetumor cells averts stemness and stratifies drug sensitivity. Cancer Research, 75(18), 3970–3979. https://doi.org/10.1158/0008-5472.CAN-15-0234CrossRef

52.

Cher, M. L., Biliran, H. R., Jr., Bhagat, S., Meng, Y., Che, M., Lockett, J., Abrams, J., Fridman, R., Zachareas, M., & Sheng, S. (2003). Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proceedings of the National Academy of Sciences of the USA, 100(13), 7847–7852. https://doi.org/10.1073/pnas.1331360100CrossRef

53.

Dzinic, S. H., Chen, K., Thakur, A., Kaplun, A., Bonfil, R. D., Li, X., Liu, J., Bernardo, M. M., Saliganan, A., Back, J. B., Yano, H., Schalk, D. L., Tomaszewski, E. N., Beydoun, A. S., Dyson, G., Mujagic, A., Krass, D., Dean, I., Mi, Q. S., Heath, E., Sakr, W., Lum, L. G., & Sheng, S. (2014). Maspin expression in prostate tumor elicits host anti-tumor immunity. Oncotarget, 5(22), 11225–11236. https://doi.org/10.18632/oncotarget.2615.

54.

Dzinic, S. H., Bernardo, M. M., Oliveira, D. S., Wahba, M., Sakr, W., & Sheng, S. (2015). Tumor suppressor maspin as a modulator of host immune response to cancer. Bosnian Journal of Basic Medical Sciences, 15(4), 1–6. https://doi.org/10.17305/bjbms.2015.783.

55.

Bascones-Martinez, A., Lopez-Duran, M., Cano-Sanchez, J., Sanchez-Verde, L., Diez-Rodriguez, A., Aguirre-Echebarria, P., Alvarez-Fernandez, E., Gonzalez-Moles, M. A., Bascones-Ilundain, J., Muzio, L. L., & Campo-Trapero, J. (2012). Differences in the expression of five senescence markers in oral cancer, oral leukoplakia and control samples in humans. Oncology Letters, 3(6), 1319–1325. https://doi.org/10.3892/ol.2012.649CrossRef

56.

Band, V., & Sager, R. (1989). Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. Proceedings of the National Academy of Sciences of the USA, 86(4), 1249–1253. https://doi.org/10.1073/pnas.86.4.1249CrossRef

57.

Sfanos, K. S., Yegnasubramanian, S., Nelson, W. G., & De Marzo, A. M. (2018). The inflammatory microenvironment and microbiome in prostate cancer development. Nature Reviews Urology, 15(1), 11–24. https://doi.org/10.1038/nrurol.2017.167CrossRef

58.

Marioni, G., Blandamura, S., Lionello, M., Giacomelli, L., Staffieri, C., Fasanaro, E., Manzato, E., & Staffieri, A. (2011). Nuclear MASPIN expression relates to a better prognosis in elderly patients with laryngeal carcinoma. Acta Otolaryngology, 131(11), 1220–1225. https://doi.org/10.3109/00016489.2011.599817CrossRef

59.

Ruppender, N. S., Morrissey, C., Lange, P. H., & Vessella, R. L. (2013). Dormancy in solid tumors: Implications for prostate cancer. Cancer & Metastasis Reviews, 32(3–4), 501–509. https://doi.org/10.1007/s10555-013-9422-zCrossRef

60.

Tu, S. M., & Lin, S. H. (2012). Prostate cancer stem cells. Clinical Genitourinary Cancer, 10(10), 69–76. https://doi.org/10.1016/j.clgc.2012.01.002CrossRef

61.

Naujokat, C., & Steinhart, R. (2012). Salinomycin as a drug for targeting human cancer stem cells. J Biomedicine & Biotechnology, 2012, 950658. https://doi.org/10.1155/2012/950658CrossRef

62.

Berner, F., Bomze, D., Diem, S., Ali, O. H., Fassler, M., Ring, S., Niederer, R., Ackermann, C. J., Baumgaertner, P., Pikor, N., Cruz, C. G., van de Veen, W., Akdis, M., Nikolaev, S., Laubli, H., Zippelius, A., Hartmann, F., Cheng, H. W., Honger, G., … Flatz, L. (2019). Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncology, 5(7), 1–6. https://doi.org/10.1001/jamaoncol.2019.0402CrossRef

63.

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W., Schellhammer, P. F., & Impact Study Investigators. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine, 363(5), 411-422. https://doi.org/10.1056/NEJMoa1001294.

64.

Thakur, A., Lum, L. G., Hwang, C., Paller, C. J., Schalk, D. L., Kondadasular, V., Heilrun, L. K., & Heath, E.I. (2017). Immune evaluation study of sipuleucel-T (Sip-T) in African-American and European-American men with castration-resistant prostate cancer. Journal of Clinical Oncology, 35(Supplement S6), 206. https://doi.org/10.1200/JCO.2017.35.6_suppl.206

65.

Gulley, J. L., Madan, R. A., Pachynski, R., Mulders, P., Sheikh, N. A., Trager, J., & Drake, C. G. (2017). Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. Journal of the National Cancer Institute, 109(4), djw261. https://doi.org/10.1093/jnci/djw261.

66.

De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Gronberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., & Nelson, W. G. (2007). Inflammation in prostate carcinogenesis. Nature Reviews Cancer, 7(4), 256–269. https://doi.org/10.1038/nrc2090CrossRef

67.

Dean, I., Dzinic, S. H., Bernardo, M. M., Zou, Y., Kimler, V., Li, X., Kaplun, A., Granneman, J., Mao, G., & S. Sheng, S. (2017). The secretion and biological function of tumor suppressor maspin as an exosome cargo protein. Oncotarget, 8 (2017 5) 8043–8056. https://doi.org/10.18632/oncotarget.13302.

Title: The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin
Authors: Shijie Sheng
Margarida Bernardo
Sijana H. Dzinic
Kang Chen
Wael A. Sakr
Publication date: 01-12-2022
Publisher: Springer US
Keywords: Prostate Cancer
Prostate Cancer
Published in: Cancer and Metastasis Reviews / Issue 4/2022
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-022-10070-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2022

Message in the bottle: regulation of the tumor microenvironment via exosome-driven proteolysis

Physicochemical aspects of the tumour microenvironment as drivers of vasculogenic mimicry

The multifaceted mechanisms of malignant glioblastoma progression and clinical implications

Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling

The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options

p73 isoforms meet evolution of metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer